Physician profile
Constance Mudda
NPI 1083292148
$687.08
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.06 · 2024: $480 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $374.09 | 2024-2025 | Breztri, Lokelma, Airsupra |
| Abbvie INC. | $53.05 | 2024-2025 | |
| Dexcom, INC. | $50.49 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $41.06 | 2022 | |
| Lilly USA, LLC | $33.35 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $31.07 | 2025 | Rybelsus, Ozempic |
| Amgen INC. | $28.14 | 2024 | Otezla, Repatha |
| Eisai INC. | $20.84 | 2025 | |
| Astellas Pharma US INC | $19.48 | 2024 | Veozah |
| Inari Medical, INC. | $18.56 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $16.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Mudda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.